BRPI0507649A - molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit - Google Patents
molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kitInfo
- Publication number
- BRPI0507649A BRPI0507649A BRPI0507649-8A BRPI0507649A BRPI0507649A BR PI0507649 A BRPI0507649 A BR PI0507649A BR PI0507649 A BRPI0507649 A BR PI0507649A BR PI0507649 A BRPI0507649 A BR PI0507649A
- Authority
- BR
- Brazil
- Prior art keywords
- binding molecule
- nucleic acid
- acid sequence
- bispecifically
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Adhesives Or Adhesive Processes (AREA)
Abstract
MOLéCULA DE LIGAçãO BIESPECìFICA, SEQüENCIA DE áCIDO NUCLéICO, VETOR, PROCESSO PARA A PRODUçãO DA MOLéCULA DE LIGAçãO BIESPECìFICA, COMPOSIçãO, USO DA MOLéCULA DE LIGAçãO BIESPECìFICA NA PREPARAçãO DA COMPOSIçãO FARMACêUTICA, E KIT A presente invenção provê uma molécula de ligação biespecífica em que dita molécula compreende ou consiste de pelo menos dois domínios, sendo que um de ditos pelo menos dois domínios especificamente se liga a/interage com o complexo CD3 humano e dito domínio compreende uma seqüencia de aminoácidos de uma cadeia curta derivada de anticorpo, em que dita seqüencia de aminoácidos é uma seqüencia de aminoácidos particurlamente identificada compreendendo substituições de aminoácido específico, e um segundo domínio que é ou contém pelo menos um sítio-de-interação-com-antígeno e/ou pelo menos um domínio efetor adicional. A invenção provê ainda moléculas de ácido nucléico codificantes de moléculas de ligação biespecíficas da invenção, vetores compreendendo ditas moléculas de ácido nucléico e células de hospedeiro transformadas ou transfectadas com ditos vetores. Além disso, a invenção diz respeito a um método para produção de moléculas de ligação biespecíficas da invenção e composições compreendendo as moléculas de ligação biespecíficas da invenção, as moléculas de ácido nucleico da invenção ou as células de hospedeiro da invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04003445 | 2004-02-16 | ||
| PCT/EP2005/001573 WO2005077982A1 (en) | 2004-02-16 | 2005-02-16 | Less immunogenic binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507649A true BRPI0507649A (pt) | 2007-07-10 |
Family
ID=34854553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507649-8A BRPI0507649A (pt) | 2004-02-16 | 2005-02-16 | molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8101722B2 (pt) |
| EP (1) | EP1716178B1 (pt) |
| JP (1) | JP4762158B2 (pt) |
| KR (1) | KR20060131892A (pt) |
| CN (1) | CN1950399A (pt) |
| AT (1) | ATE477277T1 (pt) |
| AU (1) | AU2005212830B2 (pt) |
| BR (1) | BRPI0507649A (pt) |
| CA (1) | CA2555503C (pt) |
| DE (1) | DE602005022830D1 (pt) |
| DK (1) | DK1716178T3 (pt) |
| IL (1) | IL177337A0 (pt) |
| MX (1) | MXPA06009253A (pt) |
| RU (1) | RU2006132669A (pt) |
| SI (1) | SI1716178T1 (pt) |
| WO (1) | WO2005077982A1 (pt) |
| ZA (1) | ZA200606410B (pt) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2005249396B2 (en) * | 2004-05-05 | 2011-10-20 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| AU2006272555B2 (en) | 2005-07-25 | 2012-03-08 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| US8236308B2 (en) * | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| ATE509033T1 (de) | 2006-03-20 | 2011-05-15 | Univ California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| PL2155788T3 (pl) * | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| US20100047164A1 (en) * | 2008-04-11 | 2010-02-25 | Duke University | Anti-Tumor Antibodies |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| MX2011003502A (es) * | 2008-10-01 | 2011-09-01 | Micromet Ag | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. |
| KR101837053B1 (ko) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 |
| JP5906090B2 (ja) | 2009-02-17 | 2016-04-20 | コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ | 癌の診断のための方法およびキットならびに治療価の推定 |
| CA3040276A1 (en) | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| CA2815277A1 (en) * | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Novel egfr-binding molecules and immunoconjugates thereof |
| US9249217B2 (en) | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
| BR112013027224A8 (pt) | 2011-04-22 | 2018-08-14 | Emergent Product Dev Seattle | Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados |
| CN102898527B (zh) * | 2011-07-25 | 2016-12-21 | 三星电子株式会社 | 融合蛋白、药物组合物及预防或治疗癌症的方法 |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| AU2012340174A1 (en) | 2011-11-16 | 2014-05-29 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant VIII related disorders |
| IN2014MN02293A (pt) | 2012-04-20 | 2015-08-07 | Emergent Product Dev Seattle | |
| EP2892924B1 (en) * | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| ES2978993T3 (es) * | 2014-02-21 | 2024-09-23 | Ibc Pharmaceuticals Inc | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| US20170058043A1 (en) | 2014-12-06 | 2017-03-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bispecific antibody for cancer immunotherapy |
| JP7095992B2 (ja) * | 2014-12-08 | 2022-07-05 | １グローブ バイオメディカル カンパニー， リミテッド | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
| KR20170095364A (ko) * | 2014-12-18 | 2017-08-22 | 비오메리으 | 합성 이중-에피토프 화합물 |
| EP3250602A1 (en) * | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| SG11201705988UA (en) | 2015-02-24 | 2017-08-30 | Bioatla Llc | Conditionally active biological proteins |
| HK1253512A1 (zh) | 2015-05-29 | 2019-06-21 | Amphivena Therapeutics, Inc. | 双特异性cd33和cd3结合蛋白质的使用方法 |
| CN104892765B (zh) * | 2015-06-29 | 2018-04-10 | 深圳市国创纳米抗体技术有限公司 | 一种抗CD3抗原和Her‑2抗原的双特异性抗体 |
| CN108136012B (zh) | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| CN107446051B9 (zh) * | 2016-05-31 | 2019-02-22 | 上海恒润达生生物科技有限公司 | 靶向cd19的嵌合抗原受体及其用途 |
| CN106084044A (zh) * | 2016-06-24 | 2016-11-09 | 安徽未名细胞治疗有限公司 | 一种人鼠嵌合抗MESO的全分子IgG抗体及其应用 |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| KR20190140943A (ko) | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体 |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN110042127A (zh) * | 2019-04-23 | 2019-07-23 | 北京市心肺血管疾病研究所 | 向心肌细胞递送目标核酸分子的制剂、其制备方法及应用 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| WO2021198204A1 (en) * | 2020-03-30 | 2021-10-07 | Sanofi | Split ch2 domains |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6129914A (en) * | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| WO1998047531A2 (en) * | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| CA2326389C (en) * | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| JP3803790B2 (ja) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| NZ543202A (en) * | 2003-05-31 | 2008-04-30 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for epcam |
-
2005
- 2005-02-16 BR BRPI0507649-8A patent/BRPI0507649A/pt not_active IP Right Cessation
- 2005-02-16 CA CA2555503A patent/CA2555503C/en not_active Expired - Lifetime
- 2005-02-16 DK DK05715354.6T patent/DK1716178T3/da active
- 2005-02-16 JP JP2006552576A patent/JP4762158B2/ja not_active Expired - Lifetime
- 2005-02-16 WO PCT/EP2005/001573 patent/WO2005077982A1/en not_active Ceased
- 2005-02-16 EP EP05715354A patent/EP1716178B1/en not_active Expired - Lifetime
- 2005-02-16 RU RU2006132669/13A patent/RU2006132669A/ru not_active Application Discontinuation
- 2005-02-16 ZA ZA200606410A patent/ZA200606410B/en unknown
- 2005-02-16 AU AU2005212830A patent/AU2005212830B2/en not_active Expired
- 2005-02-16 US US10/588,734 patent/US8101722B2/en active Active
- 2005-02-16 SI SI200531118T patent/SI1716178T1/sl unknown
- 2005-02-16 DE DE602005022830T patent/DE602005022830D1/de not_active Expired - Lifetime
- 2005-02-16 AT AT05715354T patent/ATE477277T1/de not_active IP Right Cessation
- 2005-02-16 CN CNA200580008594XA patent/CN1950399A/zh active Pending
- 2005-02-16 KR KR1020067018976A patent/KR20060131892A/ko not_active Withdrawn
- 2005-02-16 MX MXPA06009253A patent/MXPA06009253A/es unknown
-
2006
- 2006-08-07 IL IL177337A patent/IL177337A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1716178B1 (en) | 2010-08-11 |
| CN1950399A (zh) | 2007-04-18 |
| RU2006132669A (ru) | 2008-03-27 |
| IL177337A0 (en) | 2006-12-10 |
| DE602005022830D1 (de) | 2010-09-23 |
| SI1716178T1 (sl) | 2010-11-30 |
| ATE477277T1 (de) | 2010-08-15 |
| EP1716178A1 (en) | 2006-11-02 |
| AU2005212830B2 (en) | 2011-06-02 |
| JP4762158B2 (ja) | 2011-08-31 |
| WO2005077982A1 (en) | 2005-08-25 |
| CA2555503A1 (en) | 2005-08-25 |
| CA2555503C (en) | 2018-03-27 |
| ZA200606410B (en) | 2007-12-27 |
| MXPA06009253A (es) | 2007-04-18 |
| AU2005212830A1 (en) | 2005-08-25 |
| US20080213256A1 (en) | 2008-09-04 |
| JP2008506353A (ja) | 2008-03-06 |
| KR20060131892A (ko) | 2006-12-20 |
| US8101722B2 (en) | 2012-01-24 |
| DK1716178T3 (da) | 2010-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014010630A2 (pt) | moléculas de ligação para bcma e cd3 | |
| DK1716178T3 (da) | Mindre immunogene bindingsmolekyler | |
| BR112015020277A2 (pt) | moléculas de ligação para bcma e cd3 | |
| BR112015017548A8 (pt) | construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit | |
| BR112012024964A2 (pt) | anticorpo de cadeia única bioespecífico psmaxcd3 de espécies cruzadas específicas, seu processso de preparação, seu uso, vetor, composição farmacêutica e kit | |
| BRPI0620946A8 (pt) | anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica | |
| BRPI0917470B8 (pt) | anticorpo anti-lag-3 ou uma porção de ligação ao antígeno do mesmo, seu método de preparação, seus usos, composição, imunoconjugado, molécula de ácido nucleico isolado, vetor de expressão e método de estímulo de uma resposta de células t antígenoespecífica | |
| BRPI0922350B8 (pt) | anticorpo humano que se liga ao fator de tecido humano e molécula biespecífica e seus usos, célula hospedeira eucariótica ou procariótica recombinante, composição farmacêutica, método para a produção de um anticorpo, composição de diagnóstico, método para detectar a presença de fator de tecido em uma amostra in vitro, kit para detectar a presença de fator de tecido em uma amostra eanticorpo antiidiotípico | |
| CL2011001431A1 (es) | Molecula de anticuerpo humano que se une al factor de crecimiento insulinico tipo 1 (igf-1) y tipo 2 (igf-2) humano, de raton y rata, y no se enlaza a insulina humana; molecula de adn que la codifica; vector, celula hospedante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| BR112018001638A2 (pt) | construtos de anticorpo biespecífico que se ligam à mesotelina e cd3 | |
| BR112012030664A2 (pt) | proteína de ligação de antígeno humanizada, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para a produção de uma proteína de ligação de antígeno, para tratar um indivíduo afligido com uma doença e para aumentar a massa muscular, aumentar a força muscular, e/ou melhorar a função muscular em um paciente, e, composição farmacêutica. | |
| BRPI0507489A (pt) | anticorpos humanos de anti-cd38 e para os seus usos | |
| BR122017021516B8 (pt) | processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia | |
| MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
| MX2010000537A (es) | Anticuerpos monoclonales contra glipicano-3. | |
| BRPI0410238A (pt) | compostos orgánicos | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| BRPI0500474A (pt) | adsorção de ácidos nucléicos para uma fase sólida | |
| BR112014015339A2 (pt) | compostos para inibição da interação de bcl2 com parceiros de ligação | |
| AR078516A1 (es) | Moleculas de union a dll-4 (ligando 4 de tipo delta) | |
| BR112014015274A8 (pt) | compostos e composições para inibição da interação de bcl2 com parceiros de ligação | |
| BRPI0607765A2 (pt) | pirazolopirimidinas | |
| BRPI0916069C1 (pt) | composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição | |
| BRPI0512928A (pt) | composições e métodos para liberação de agentes de antitumor | |
| BRPI0411738A (pt) | compostos orgánicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 5A E 6A ANUIDADE(S) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |